Not available
Quote | Antisense Therapeutics (OTCMKTS:ATHJF)
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.01 |
Close: | $0.01 |
High: | $0.01 |
Low: | $0.01 |
Volume: | 24,000 |
Last Trade Date Time: | 12/28/2023 03:00:00 am |
News | Antisense Therapeutics (OTCMKTS:ATHJF)
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George ...
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-revie...
Message Board Posts | Antisense Therapeutics (OTCMKTS:ATHJF)
Subject | By | Source | When |
---|---|---|---|
next sarepta here is possible | BioSpecialist | investorshub | 08/08/2019 2:12:54 PM |
phase 2 results of the DMD trial in | BioSpecialist | investorshub | 08/08/2019 2:12:19 PM |
huge upside potential here | BioSpecialist | investorshub | 08/08/2019 2:11:49 PM |
hello | BioSpecialist | investorshub | 08/08/2019 2:11:20 PM |
Stock_Tracker: Latest Antisense Therap Ltd (ATHJF) Headlines Antisense Therapeutics Selected to Pres | Stock_Tracker | investorshangout | 03/09/2014 4:21:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Antisense Therapeutics Company Name:
ATHJF Stock Symbol:
OTCMKTS Market:
Antisense Therapeutics Website:
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George ...
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-revie...
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received approval from the Royal Children's Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a ...